Brett King, MD, PhD: Value of LEVEL UP Data and Pushing New Standards in Dermatology
Brett King, MD, PhD, discusses the LEVEL UP trial and how it represents the field of dermatology's desire to advance care and advocate for new standards of care.
Twice-Daily Delgocitinib Improved Patient Reported Outcomes for Chronic Hand Eczema
These data, presented at RAD 2024, highlight the potential of delgocitinib cream for patients with chronic hand eczema in terms of patient and clinician reported outcomes.
Risk of Malignancy, Major Adverse Cardiovascular Events in Patients with Atopic Dermatitis
These findings, presented at RAD 2024, highlight risk of atopic dermatitis patients for developing various cancers as well as major adverse cardiovascular events.
Dupilumab Versus Lebrikizumab with Topical Corticosteroids: Efficacy in Atopic Dermatitis
These data highlighted which drug, in combination with topical corticosteroids, produced the best efficacy results for those with atopic dermatitis.
Upadacitinib Led to Sustained, 140-Week Improvements for Atopic Dermatitis Patients
These data, presented at RAD 2024, highlight the potential benefits of upadacitinib for adults and adolescents observed in the Measure Up 1 and Measure Up 2 studies.
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
Sidbury covered the similarities and differences between the new guideline updates by the AAD on atopic dermatitis as well as differences with other organizations’ guidelines.
Moderate-to-Severe Alopecia Areata Patients More Likely Than Mild Cases to Develop Eczema
In new late-breaking data, alopecia patients’ real-world incidence of atopic dermatitis was highlighted by investigators.
Discrete Choice Experiment: Treatment Preferences of Atopic Dermatitis Patients
These data presented at RAD 2024 highlight the differences among eczema patient preferences in terms of administration modes, risk levels, and more.
Report Details Racial/Ethnic Differences in Treatment Satisfaction, Provider Trust in Atopic Dermatitis
An analysis of survey data from more than 200 patients with atopic dermatitis details treatment satisfaction and provider trust based on racial/ethnic backgrounds of patients.
Eczema Patients Treated with Upadacitinib in Real World Setting See Significant Improvements
This late-breaking data featured at RAD 2024 highlights several improvements in patient reported outcomes observed among atopic dermatitis patients, including itch relief.
Robert Bissonnette, MD: Highlighting Recent Findings on Topical Treatments for Atopic Dermatitis
This interview at RAD 2024 featured a discussion by Bissonnette of recent data related to 4 topical drugs for patients with atopic dermatitis.
ARCADIA: Nemolizumab Achieves Significant Itch Reduction by Day 2 of Treatment
A post-hoc analysis of the ARCADIA program provides insight into the speed of itch relief onset observed with nemolizumab among patients with moderate-to-severe atopic dermatitis.
Robert Bissonnette, MD: Discussing Recent Data on Topical Therapies for Atopic Dermatitis
In his RAD 2024 talk, Bissonnette presented recent data on 4 topical drugs for atopic dermatitis, including crisaborole and ruxolitinib.
Jonathan Silverberg, MD, PhD, MPH: LEVEL UP Aids in Clinical Decision-Making for Atopic Dermatitis
Jonathan Silverberg, MD, PhD, MPH, discusses how the results of the LEVEL UP trial impact treatment decisions for patients with moderate-to-severe atopic dermatitis.
LEVEL UP: Upadacitinib Bests Dupilumab for Moderate-to-Severe Atopic Dermatitis
LEVEL UP data presented at RAD 2024 provide additional insight into the phase 3b/4 trial comparing upadacitinib and dupilumab in atopic dermatitis beyond the primary endpoint.
Ruxolitinib Consistent in Safety, Tolerability Over 52-Weeks in Children with Extensive Atopic Dermatitis
Treating eczema twice-daily with ruxolitinib cream, 1.5% led to positive results for children in the age range of 2 to 11 years.
Roflumilast Cream 0.15% Safe for Long-Term Use in Atopic Dermatitis Patients
In this open-label extension trial presented at RAD 2024, the long-term safety and efficacy results of roflumilast cream in adults and children with eczema was highlighted.
David Rosmarin, MD: Futuristic Therapies for Atopic Dermatitis
Rosmarin discussed several treatments in development covered in his RAD 2024 presentation for the treatment of patients with eczema.
Study Links Atopic Dermatitis to 36% Increase in Risk of Nonmelanoma Skin Cancers
Study from RAD 2024 finds 36% higher risk of nonmelanoma skin cancer in patients with atopic dermatitis relative to matched controls.
‘Can We Achieve Atopic Dermatitis Remission with Current Therapies?’ with Raj Chovatiya, MD, PhD
In this interview, Chovatiya spoke about his second RAD 2024 talk regarding achieving remission with currently available eczema treatments.
Open-Label Data Suggests No Increased Risk of Infections with Long-Term Dupilumab Use
An analysis of data from the LIBERTY AD trial presented at RAD 2024 details the risk of infections observed with dupilumab use with up to 5 years of follow-up.
Raj Chovatiya, MD, PhD: How Do Approved Eczema Treatments Compare?
This RAD 2024 interview featured a discussion of currently FDA-approved atopic dermatitis therapies and their comparisons.
Tips for Giving Shots to Children with Atopic Dermatitis, with Amy Paller, MD
This segment of Paller’s RAD 2024 interview covers tips for treating children with biologics as well as unmet needs of eczema patients and upcoming treatments.
Chronic Itch Linked to Doubling in Risk of Fatigue for Many Skin Conditions
An analysis of data from the NIH's All of Us program details the prevalence of fatigue among patients with pruritus among US patients.
How to Manage Atopic Comorbidities Among Atopic Dermatitis Patients, with Anne Marie Singh, MD
In her presentation at RAD 2024, Singh highlighted ways to manage the atopic comorbidities linked to eczema in children.
Study Highlights Real-World Data on Efficacy, Daily Clinical Use of Tralokinumab for Atopic Dermatitis
The global, real-world TRACE study was designed to improve the understanding of tralokinumab’s safety, efficacy, and clinical utilization in daily practice for eczema.
Amy Paller, MD: What Treatments Can Be Used in Pediatric Patients with Eczema?
In her RAD conference interview, Paller describes several treatments featured in her talk on the subject of pediatric eczema.
Real-World Data Highlights Effectiveness of Tralokinumab in Atopic Dermatitis
A real-world analysis of 60 patients suggests traolkinumab was effective in atopic dermatitis, regardless of prior therapy use.
Systemic Therapies Coming Soon for Atopic Dermatitis, with Jonathan Silverberg, MD, PhD
This interview with Silverberg featured a discussion of new data on systemic therapies for various dermatologic conditions.
Jonathan Silverberg, MD, PhD: How to Help Manage Autoimmune Comorbidities of Atopic Dermatitis
In an interview at RAD 2024, Silverberg discusses ways to help patients navigate such comorbidities associated with eczema.
